Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available.
CANbridge Pharmaceuticals Inc. announced that its product, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval in the PRC for treating type I and III Gaucher disease. This approval marks a significant milestone as Gaurunning is the first domestically developed enzyme replacement therapy for these conditions, potentially enhancing medication accessibility for patients in China and strengthening CANbridge’s position in the rare disease treatment market.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company based in the PRC, focusing on research, development, and commercialization of transformative therapies for rare diseases. The company has a diverse drug portfolio with three approved drugs and a pipeline targeting rare disease indications with unmet needs, such as Hunter syndrome, lysosomal storage disorders, and neuromuscular diseases. They are also developing gene therapies for rare genetic diseases like Duchenne muscular dystrophy.
Average Trading Volume: 1,287,214
Technical Sentiment Signal: Sell
Current Market Cap: HK$58.63M
For a thorough assessment of 1228 stock, go to TipRanks’ Stock Analysis page.